Analysts have moved decisively in COHR's favour ahead of today's after-market earnings, with target prices rising sharply and the bull camp gathering momentum even as the stock has already run 30% higher in a month.
The clearest signal heading into the print is the weight of analyst conviction on the upside. Stifel lifted its target to $412 from $275 — a 50% increase — just yesterday, reaffirming its Buy. Citi raised its target to $420 from $250 earlier in April. Rothschild initiated with a Buy and a $455 target last week. Even JPMorgan, maintaining its Overweight, moved to $300 from $245 in April. Morgan Stanley is the lonely exception, keeping its Equal-Weight stance with a $290 target — well below the $326 consensus mean. The aggregate direction is unmistakably bullish, with the majority of targets now sitting well above where the stock traded just six weeks ago.
The debate between bulls and bears centres on capacity and dependency. Bulls point to COHR's diversified product suite, expanding partnerships in the datacom and transceiver markets, and the company's organic indium phosphide capacity build-out — a projected 90% increase over four years — as structural growth drivers. Bears counter that limited InP capacity relative to peers, reliance on the Chinese datacom market, and meaningful FX and debt exposure leave margins vulnerable. On valuation, the re-rating has been material: the P/E has expanded by roughly 10 points over the past 30 days to roughly 54x, and the EV/EBITDA is running near 36x. The analyst recommendation differential ranks in the 94th percentile, suggesting the Street is more constructive on COHR than on almost any other name in the universe — but the multiples leave limited room for disappointment.
Insider activity has leaned modestly toward the sell side. The CFO sold 2,000 shares at $351 in late April, and a cluster of director sales occurred in March at prices ranging from $236 to $291. The net 90-day transaction value is just over $5.6 million in sales. These were small transactions relative to the company's scale, each carrying a low significance score, and the directional message is consistent with profit-taking after a strong run rather than a fundamental concern. On the institutional side, FMR (Fidelity) added over 10 million shares to reach 11.9% of shares outstanding by end of March — a substantial build that provides structural demand support.
Short positioning is not the story here. At just under 6% of the free float, short interest has been on a steady retreat — down roughly 10% over the past month — while borrow availability remains wide open and cost to borrow is negligible at 0.37%. Options positioning is broadly neutral: the put/call ratio of 1.01 is barely above its 20-day average and well inside either end of its 52-week range. After the February print, the stock fell roughly 8.7% on the day before recovering partially over five sessions — meaning the market has seen this name punished on results before, even when the broader setup looked constructive.
Today's print is therefore less about whether COHR's optical networking business is growing and more about whether the capacity expansion story is translating into margin delivery at a P/E that has almost doubled in two months.
See the live data behind this article on ORTEX.
Open COHR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
